Edmond Godfroid, PhD (Chief Executive Officer)
Before founding Bioxodes, Edmond Godfroid was a long standing senior professor at the University of Brussels (ULB) where he applied his expertise in molecular biology to the discovery of pharmacologically active proteins in the saliva of the Ixodes tick. Dr Godfroid’s and his former team’s work is the basis for the creation of Bioxodes. He received his PhD in Molecular Biology from ULB in 1988 and subsequently acquired post-doctoral experience in the field of Alzheimer‘s disease at the Université Catholique de Louvain. In 1992, he joined Applied Genetics (ULB) where he developed the first PCR-based diagnostic device specific to the tick-borne bacterial pathogen, Borrelia burgdorferi, the causal agent of Lyme disease. In 1995, Dr Godfroid began research on the molecular interaction between Ixodes ticks and their hosts. Until recently he was the Head of the Ectoparasite Molecular Biology Unit at ULB and is named as inventor or co-inventor on 14 patents. Additionally he is the author or co-author of more than 50 internationally peer-reviewed papers, published in high-impact-factor journals. He has experience of a range of collaborations with academic groups and pharmaceutical companies. Professor Godfroid is a co-founder of Bioxodes.

Michel Guyaux, PhD (Preclinical Development Director)
Michel Guyaux has more then 20 years of experience in pharmaceutical research. He was latterly Senior Group Leader at the multinational biopharmaceutical firm UCB where he focussed on drug discovery research and development in the field of cardiovascular, inflammatory and CNS diseases. As project manager and head of safety pharmacology department he was actively involved in the preclinical evaluation and development programs of new therapeutical entities including small and large molecules. He is a specialist in early stage clinical and pre-clinical programs integrating toxicology, pharmacokinetics and pharmacodynamics. He obtained his PhD in chemistry from the University of Brussels (ULB) and a Master in pharmacochemistry and drug design from the University of Lille. He joined the pharmaceutical sector after postdoctoral research in oncology and parasitology in the University of California (San Francisco) and the University of Brussels (ULB), respectively. Dr Guyaux is a co-founder of Bioxodes.


Latest News

Bioxodes’ antithrombotic meets development milestones - Company to launch Series A investment round to bring product to the clinic

Marche-en-Famenne, Belgium – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products ...
Read more